Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration

EVANSTON, Ill., May 22, 2018 /PRNewswire/ -- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral...

from PR Newswire: https://ift.tt/2s4jDLt
via